Mesoblast shares: Bull vs. bear

Two experts have presented their case for buying and selling the ASX biotech stock.

Key points
  • Mesoblast anticipates significant sales growth for Ryoncil, driven by rising demand for pediatric SR-aGvHD therapy and expected revenues above US$30 million in 2Q FY26.
  • Bullish investor sentiment, highlighted by Nathan Lodge from Securities Vault, focuses on Ryoncil's revenue growth, strategic reimbursement gains, and Mesoblast's strong cash position and financing flexibility.
  • Conversely, bearish perspectives, exemplified by Andrew Wielandt from DP Wealth Advisor, underscore concerns over Mesoblast's stock volatility, historical capital raisings, and a notable level of short interest at 7%.

Mesoblast Ltd (ASX: MSB) shares are trading for $2.64, down 2.94% on Thursday.

Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is in the green today, up 0.34% at the time of writing.

The allogeneic cellular medicines developer held its annual general meeting and provided quarterly sales guidance earlier this week.

Mesoblast expects significantly higher second-quarter sales revenue due to rising demand for its flagship medicine, Ryoncil.

Ryoncil treats steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients of two months and older.

It's the first FDA-approved mesenchymal stromal cell (MSC) therapy in the market.

The FDA approved Ryoncil in December 2024, and Mesoblast released it to commercial clinics in late March this year.

The FDA also gave Ryoncil orphan-drug exclusive approval.

That means the FDA will not approve any other MSC therapies for SR-aGvHD for at least seven years.

An orphan drug is a treatment for rare diseases, which are defined as affecting fewer than 200,000 people nationwide in the US.

For 2Q FY26, Mesoblast expects gross revenue of more than US$30 million from Ryoncil sales, up 37% from 1Q FY26.

This month, two experts have presented their case for buying and selling the ASX biotech stock.

Let's hear them out.

Male investor holds a magnifying glass to his eye.

Image source: Getty Images

Bull case for Mesoblast shares

On The Bull this week, Nathan Lodge from Securities Vault revealed a buy rating on Mesoblast shares.

Lodge explains:

This regeneration therapy company offers growth momentum.

Mesoblast's lead product Ryoncil achieved meaningful revenue growth and now benefits from favourable reimbursement codes in the United States.

The company holds a strong cash position of about $US145 million and offers flexibility via a $US50 million convertible note facility to fund the next growth phase.

Company commercialisation is progressing and MSB has generated a pipeline of depth.

Bear case for ASX biotech share

On The Bull last week, Andrew Wielandt from DP Wealth Advisory put a sell rating on Mesoblast shares.

Wielandt said:

The company has been successful with its Ryoncil product since approved by the US Food and Drug Administration in late 2024.

I acknowledge research and development requires a lot of spending, but MSB has undertaken numerous capital raisings during its journey amid attracting short interest, where investors bet the share price will fall.

The share price can be volatile and has fallen from $3.35 on January 2 to trade at $2.305 on November 13.

I prefer more stable stocks.

ASIC's latest short position report shows that professional traders have short positions on 7% of the Mesoblast shares on issue today.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »